The American Cancer Society has fundamentally changed its approach to prostate cancer detection, moving away from passive suggestions toward proactive recommendations for men in their 50s and 60s. In a recent announcement, the organization revealed that it now urges men at average risk to undergo a prostate-specific antigen, or PSA, blood test every two years between the ages of 50 and 69. This marks a significant departure from previous guidance, which merely suggested that patients discuss the possibility of screening with their doctors.
Dr. Andrew Wolf, a physician at the University of Virginia and lead author of the new guidelines, explains that this shift comes after a decade of accumulating evidence showing that PSA tests are more effective at reducing deaths and preventing metastatic disease than once believed. While early studies created controversy regarding whether the benefits outweighed the risks of overdiagnosis, newer data suggests that screening is comparable in efficacy to other routine checks like mammograms. Additionally, modern medical advancements have helped minimize common pitfalls such as false positives and unnecessary treatments for slow-growing tumors.
Recognizing that risk is not uniform across all populations, the updated guidelines call for more aggressive monitoring for certain groups. Black men and those with a strong family history of the disease are encouraged to begin annual screenings starting at age 45. Dr. Wolf notes that Black men face an approximately two-thirds higher risk of developing prostate cancer and often deal with more advanced stages of the illness upon diagnosis due to various genetic and systemic healthcare factors.
As men enter their seventies, however, the advice becomes more nuanced. For those aged 70 to 74, the society recommends personalized consultations with providers to weigh individual health status against potential benefits. Once a man reaches age 75, screening is generally advised against entirely, as the risks associated with invasive follow-up procedures typically outweigh any possible advantages at that stage of life. Furthermore, the agency now advises against using digital rectal exams as primary screening tools, noting they are far less effective than simple blood draws.




